Bafna Pharmaceuticals Limited (IN:BAFNAPH)
:BAFNAPH
Top Page
Bafna Pharmaceuticals Limited
(BAFNAPH)
Select Model
Select Model
Rating:66Neutral
Price Target:
₹157.00
▲(1.52% Upside)
Action:ReiteratedDate:04/11/26
The score is driven primarily by solid financial performance trends (especially historical revenue growth) and strong technical uptrend/momentum, but is meaningfully held back by expensive valuation (high P/E) and weaker quality signals in profitability and free cash flow stability.
Positive Factors
Historical Revenue Growth
Multi-year revenue expansion indicates durable demand and successful market penetration for Bafna's products. A growing top line creates scale advantages, supports ongoing R&D and commercial investment, and provides a larger base to absorb cost pressures over the next 2-6 months and beyond.
Negative Factors
Profit Margin Compression
Compression in gross and net margins points to deteriorating profitability quality that can persist absent cost or pricing fixes. Lower margins reduce retained earnings and the cash available for reinvestment, making returns on new projects and resilience to cost shocks weaker over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Historical Revenue Growth
Multi-year revenue expansion indicates durable demand and successful market penetration for Bafna's products. A growing top line creates scale advantages, supports ongoing R&D and commercial investment, and provides a larger base to absorb cost pressures over the next 2-6 months and beyond.
Read all positive factors
Bafna Pharmaceuticals Limited (BAFNAPH) vs. iShares MSCI India ETF (INDA)
Market Cap
₹3.43B
Dividend YieldN/A
Average Volume (3M)1.19K
Price to Earnings (P/E)48.5
Beta (1Y)0.72
Revenue Growth-0.77%
EPS Growth2055.99%
CountryIN
Employees363
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.78
Shares Outstanding23,656,336
10 Day Avg. Volume1,123
30 Day Avg. Volume1,187
Financial Highlights & Ratios
PEG Ratio-0.98
Price to Book (P/B)2.09
Price to Sales (P/S)1.22
P/FCF Ratio-76.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bafna Pharmaceuticals Limited Business Overview & Revenue Model
Company Description
Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. The company provides delayed and sustained release, chewable, and orally disintegrating tablets. It also exports its products. Bafna Pharmaceutical...
How the Company Makes Money
null...
Bafna Pharmaceuticals Limited Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
70
Positive
Cash Flow
65
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.42B | 1.46B | 1.52B | 1.15B | 851.40M | 712.18M |
| Gross Profit | 408.55M | 168.77M | 452.15M | 387.56M | 338.60M | 257.62M |
| EBITDA | 167.13M | 117.73M | 146.34M | 189.88M | 112.34M | 103.94M |
| Net Income | 87.72M | 41.52M | 73.48M | 113.38M | 52.16M | 58.27M |
Balance Sheet | ||||||
| Total Assets | 1.61B | 1.53B | 1.48B | 1.30B | 901.45M | 864.66M |
| Cash, Cash Equivalents and Short-Term Investments | 19.67M | 34.33M | 13.96M | 78.09M | 194.00K | 18.04M |
| Total Debt | 324.03M | 281.99M | 243.89M | 229.24M | 110.59M | 130.00M |
| Total Liabilities | 694.55M | 682.73M | 668.43M | 561.29M | 281.81M | 296.95M |
| Stockholders Equity | 912.28M | 848.07M | 808.39M | 734.55M | 619.64M | 567.71M |
Cash Flow | ||||||
| Free Cash Flow | -71.04M | -23.31M | -60.93M | -32.66M | 21.87M | -197.04M |
| Operating Cash Flow | 93.13M | 195.29M | 94.85M | 49.52M | 97.28M | -136.09M |
| Investing Cash Flow | -149.13M | -213.02M | -150.54M | -74.93M | -65.44M | -53.45M |
| Financing Cash Flow | 24.23M | 38.09M | -8.45M | 101.77M | -48.15M | 122.80M |
Bafna Pharmaceuticals Limited Technical Analysis
Positive
154.65
Price Trends
115.42
Positive
132.91
Positive
125.95
Positive
Market Momentum
3.59
Negative
72.32
Negative
91.44
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BAFNAPH, the sentiment is Positive. The current price of 154.65 is above the 20-day moving average (MA) of 114.70, above the 50-day MA of 115.42, and above the 200-day MA of 125.95, indicating a bullish trend. The MACD of 3.59 indicates Negative momentum. The RSI at 72.32 is Negative, neither overbought nor oversold. The STOCH value of 91.44 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:BAFNAPH.
Bafna Pharmaceuticals Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ₹3.43B | 48.53 | ― | ― | -0.77% | 2055.99% | |
64 Neutral | ₹1.46B | 21.48 | ― | ― | 14.53% | -10.49% | |
58 Neutral | ₹1.20B | 16.40 | ― | 1.62% | -9.07% | 5.36% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ₹1.95B | 84.53 | ― | ― | -17.47% | -50.07% | |
50 Neutral | ₹483.71M | -1.11 | ― | ― | -24.55% | -310.57% | |
45 Neutral | ₹1.27B | -11.90 | ― | ― | -46.31% | -26.28% |
* Healthcare Sector Average
IN:BAFNAPH
Bafna Pharmaceuticals Limited
145.00
70.10
93.59%
IN:AAREYDRUGS
Aarey Drugs & Pharmaceuticals Ltd.
68.65
15.76
29.80%
IN:ALPA
Alpa Laboratories Limited
69.53
-38.92
-35.89%
IN:BALPHARMA
Bal Pharma Limited
75.32
-29.80
-28.35%
IN:KREBSBIO
Krebs Biochemicals & Industries Ltd.
58.97
-17.53
-22.92%
IN:MANGALAM
Mangalam Drugs & Organics Ltd.
30.56
-52.43
-63.18%
Bafna Pharmaceuticals Limited Corporate Events
Bafna Pharmaceuticals Shuts Trading Window Ahead of FY26 Results
Mar 26, 2026
Bafna Pharmaceuticals has announced the closure of its trading window for designated persons and their immediate relatives from April 1, 2026, until 48 hours after the declaration of audited financial results for the quarter and financial year end...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.